Evolving role of biomarkers in acute cerebrovascular disease

Annals of Neurology

Volumn 71, Issue 3, 2012, Pages 289-303

  Kernagis, Dawn N ^a   Laskowitz, Daniel T ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; D DIMER; DJ 1 PROTEIN; FIBRINOGEN; FIBRONECTIN; GELATINASE B; GLIAL FIBRILLARY ACIDIC PROTEIN; HEMOGLOBIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; MALONALDEHYDE; MYELIN BASIC PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEURON SPECIFIC ENOLASE; NUCLEOSIDE DIPHOSPHATE KINASE A; OXIDIZED LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN S100B; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ARTICLE; ATHEROSCLEROSIS; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN NERVE CELL; CELL DEATH; CEREBROVASCULAR DISEASE; CLINICAL DECISION MAKING; CLINICAL RESEARCH; COMPUTER ASSISTED TOMOGRAPHY; CONSULTATION; DIAGNOSTIC ACCURACY; DISEASE EXACERBATION; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; GENE EXPRESSION PROFILING; HEMOSTASIS; HIGH THROUGHPUT SCREENING; HUMAN; HYPERTENSION; IMMUNE RESPONSE; INFLAMMATION; LIPID PEROXIDATION; MICROGLIA; NERVE CELL LESION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PATIENT CARE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REPERFUSION; STROKE; TRANSIENT ISCHEMIC ATTACK; UPREGULATION;

ACUTE DISEASE; ANIMALS; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; CEREBROVASCULAR DISORDERS; HUMANS; OXIDATIVE STRESS; STROKE;

EID: 84859196630     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22553     Document Type: Article

References (115)

1. Whiteley W, Chong WL, Sengupta A, Sandercock P,. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke 2009; 40: e380-e389.
2. Saenger AK, Christenson RH,. Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment. Clin Chem 2010; 56: 21-33.
3. Husseini NE, Laskowitz DT,. Clinical application of blood biomarkers in cerebrovascular disease. Exp Rev Neurother 2010; 10: 189-203.
4. Maas MB, Furie KL,. Molecular biomarkers in stroke diagnosis and prognosis. Biomark Med 2009; 3: 363-383.
5. Jin R, Yang G, Li G,. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis 2010; 38: 376-385.
6. Foerch C, Wunderlich MT, Dvorak F, et al. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke 2007; 38: 2491-2495.
7. Foerch C, du Mesnil de Rochemont R, Singer O, et al. S100B as a surrogate marker for successful clot lysis in hyperacute middle cerebral artery occlusion. J Neurol Neurosurg Psychiatry 2003; 74: 322-325.
8. Foerch C, Otto B, Singer OC, et al. Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke 2004; 35: 2160-2164.
9. Wunderlich MT, Wallesch CW, Goertler M,. Release of neurobiochemical markers of brain damage is related to the neurovascular status on admission and the site of arterial occlusion in acute ischemic stroke. J Neurol Sci 2004; 227: 49-53.
10. Abraha HD, Butterworth RJ, Bath PM, et al. Serum S-100 protein, relationship to clinical outcome in acute stroke. Ann Clin Biochem 1997; 34 (pt 4): 366-370.
11. Fassbender K, Schmidt R, Schreiner A, et al. Leakage of brain-originated proteins in peripheral blood: temporal profile and diagnostic value in early ischemic stroke. J Neurol Sci 1997; 148: 101-105.
12. Foerch C, Singer OC, Neumann-Haefelin T, et al. Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch Neurol 2005; 62: 1130-1134.
13. Missler U, Wiesmann M, Friedrich C, Kaps M,. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 1997; 28: 1956-1960.
14. Foerch C, Curdt I, Yan B, et al. Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J Neurol Neurosurg Psychiatry 2006; 77: 181-184.
15. Dvorak F, Haberer I, Sitzer M, Foerch C,. Characterisation of the diagnostic window of serum glial fibrillary acidic protein for the differentiation of intracerebral haemorrhage and ischaemic stroke. Cerebrovasc Dis 2009; 27: 37-41.
16. Jauch EC, Lindsell C, Broderick J, et al. Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke 2006; 37: 2508-2513.
17. Welsh P, Barber M, Langhorne P, et al. Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc Dis 2009; 27: 247-253.
18. Winbeck K, Poppert H, Etgen T, et al. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke 2002; 33: 2459-2464.
19. Di Napoli M, Di Gianfilippo G, Sollecito A, Bocola V,. C-reactive protein and outcome after first-ever ischemic stroke. Stroke 2000; 31: 238-239.
20. Di Napoli M, Papa F, Bocola V,. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 2001; 32: 917-924.
21. Castellanos M, Leira R, Serena J, et al. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 2004; 35: 1671-1676.
22. Castellanos M, Leira R, Serena J, et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003; 34: 40-46.
23. Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107: 598-603.
24. Tuttolomondo A, Di Sciacca R, Di Raimondo D, et al. Plasma levels of inflammatory and thrombotic/fibrinolytic markers in acute ischemic strokes: relationship with TOAST subtype, outcome and infarct site. J Neuroimmunol 2009; 215: 84-89.
25. Mocco J, Choudhri TF, Mack WJ, et al. Elevation of soluble intercellular adhesion molecule-1 levels in symptomatic and asymptomatic carotid atherosclerosis. Neurosurgery 2001; 48: 718-721; discussion 721-722.
26. DeGraba TJ, Siren AL, Penix L, et al. Increased endothelial expression of intercellular adhesion molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque. Stroke 1998; 29: 1405-1410.
27. Chamorro A, Hallenbeck J,. The harms and benefits of inflammatory and immune responses in vascular disease. Stroke 2006; 37: 291-293.
28. Anderson RE, Hansson LO, Nilsson O, et al. High serum S100B levels for trauma patients without head injuries. Neurosurgery 2001; 48: 1255-1258; discussion 1258-1260.
29. Ben Assayag E, Shenhar-Tsarfaty S, Ofek K, et al. Serum cholinesterase activities distinguish between stroke patients and controls and predict 12-month mortality. Mol Med 2010; 16: 278-286.
30. Allard L, Burkhard PR, Lescuyer P, et al. PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin Chem 2005; 51: 2043-2051.
31. Ozkul A, Akyol A, Yenisey C, et al. Oxidative stress in acute ischemic stroke. J Clin Neurosci 2007; 14: 1062-1066.
32. Cano CP, Bermudez VP, Atencio HE, et al. Increased serum malondialdehyde and decreased nitric oxide within 24 hours of thrombotic stroke onset. Am J Ther 2003; 10: 473-476.
33. Uno M, Kitazato KT, Nishi K, et al. Raised plasma oxidised LDL in acute cerebral infarction. J Neurol Neurosurg Psychiatry 2003; 74: 312-316.
34. Roberts LJ Jr, Montine TJ, Markesbery WR, et al. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 1998; 273: 13605-13612.
35. Wunderlich MT, Lins H, Skalej M, et al. Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke. Clin Neurol Neurosurg 2006; 108: 558-563.
36. Dambinova SA, Khounteev GA, Izykenova GA, et al. Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem 2003; 49: 1752-1762.
37. Laterza OF, Modur VR, Crimmins DL, et al. Identification of novel brain biomarkers. Clin Chem 2006; 52: 1713-1721.
38. Zimmermann-Ivol CG, Burkhard PR, Le Floch-Rohr J, et al. Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study. Mol Cell Proteomics 2004; 3: 66-72.
39. Olivot JM, Labreuche J, Aiach M, Amarenco P,. Soluble thrombomodulin and brain infarction: case-control and prospective study. Stroke 2004; 35: 1946-1951.
40. Barber M, Langhorne P, Rumley A, et al. Hemostatic function and progressing ischemic stroke: D-dimer predicts early clinical progression. Stroke 2004; 35: 1421-1425.
41. Barber M, Langhorne P, Rumley A, et al. D-dimer predicts early clinical progression in ischemic stroke: confirmation using routine clinical assays. Stroke 2006; 37: 1113-1115.
42. Di Napoli M, Papa F, Bocola V,. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke 2001; 32: 133-138.
43. del Zoppo GJ, Levy DE, Wasiewski WW, et al. Hyperfibrinogenemia and functional outcome from acute ischemic stroke. Stroke 2009; 40: 1687-1691.
44. Turaj W, Slowik A, Dziedzic T, et al. Increased plasma fibrinogen predicts one-year mortality in patients with acute ischemic stroke. J Neurol Sci 2006; 246: 13-19.
45. Tombul T, Atbas C, Anlar O,. Hemostatic markers and platelet aggregation factors as predictive markers for type of stroke and neurological disability following cerebral infarction. J Clin Neurosci 2005; 12: 429-434.
46. Di Napoli M, Papa F,. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke 2002; 33: 1763-1771.
47. Sato M, Suzuki A, Nagata K, Uchiyama S,. Increased von Willebrand factor in acute stroke patients with atrial fibrillation. J Stroke Cerebrovasc Dis 2006; 15: 1-7.
48. Al-Tamimi M, Gardiner EE, Thom JY, et al. Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke. Stroke 2011; 42: 498-500.
49. Kang DW, Yoo SH, Chun S, et al. Inflammatory and hemostatic biomarkers associated with early recurrent ischemic lesions in acute ischemic stroke. Stroke 2009; 40: 1653-1658.
50. Ribo M, Montaner J, Molina CA, et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke 2004; 35: 2123-2127.
51. Hernandez-Guillamon M, Garcia-Bonilla L, Sole M, et al. Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tissue plasminogen activator treatment in stroke. Stroke 2010; 41: 1528-1535.
52. Pikula A, Boger RH, Beiser AS, et al. Association of plasma ADMA levels with MRI markers of vascular brain injury: Framingham offspring study. Stroke 2009; 40: 2959-2964.
53. Makikallio AM, Makikallio TH, Korpelainen JT, et al. Natriuretic peptides and mortality after stroke. Stroke 2005; 36: 1016-1020.
54. Katan M, Fluri F, Schuetz P, et al. Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke. J Am Coll Cardiol 2010; 56: 1045-1053.
55. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-663.
56. McGirt MJ, Blessing R, Nimjee SM, et al. Correlation of serum brain natriuretic peptide with hyponatremia and delayed ischemic neurological deficits after subarachnoid hemorrhage. Neurosurgery 2004; 54: 1369-1373; discussion 1373-1374.
57. Gorelick PB,. Lipoprotein-associated phospholipase A2 and risk of stroke. Am J Cardiol 2008; 101: 34F-40F.
58. Cucchiara BL, Messe SR, Sansing L, et al. Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA. Stroke 2009; 40: 2332-2336.
59. Ovbiagele B, Starkman S, Teal P, et al. Serum calcium as prognosticator in ischemic stroke. Stroke 2008; 39: 2231-2236.
60. Huang P, Lo LH, Chen YC, et al. Serum free hemoglobin as a novel potential biomarker for acute ischemic stroke. J Neurol 2009; 256: 625-631.
61. Katan M, Fluri F, Morgenthaler NG, et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 2009; 66: 799-808.
62. Katan M, Nigro N, Fluri F, et al. Stress hormones predict cerebrovascular re-events after transient ischemic attacks. Neurology 2011; 76: 563-566.
63. Moore DF, Li H, Jeffries N, et al. Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: a pilot investigation. Circulation 2005; 111: 212-221.
64. Stamova B, Xu H, Jickling G, et al. Gene Expression Profiling of Blood for the Prediction of Ischemic Stroke. Stroke 2010; 41: 2171-2177.
65. Jickling GC, Xu H, Stamova B, et al. Signatures of cardioembolic and large-vessel ischemic stroke. Ann Neurol 2010; 68: 681-692.
66. Kleihues P, Hossmann KA,. Protein synthesis in the cat brain after prolonged cerebral ischemia. Brain Res 1971; 35: 409-418.
67. Focking M, Besselmann M, Trapp T,. Proteomics of experimental stroke in mice. Acta Neurobiol Exp (Wars) 2006; 66: 273-278.
68. Prados J, Kalousis A, Sanchez JC, et al. Mining mass spectra for diagnosis and biomarker discovery of cerebral accidents. Proteomics 2004; 4: 2320-2332.
69. Klune JR, Dhupar R, Cardinal J, et al. HMGB1: endogenous danger signaling. Mol Med 2008; 14: 476-484.
70. Bianchi ME,. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81: 1-5.
71. Goldstein RS, Gallowitsch-Puerta M, Yang L, et al. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 2006; 25: 571-574.
72. Muhammad S, Barakat W, Stoyanov S, et al. The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci 2008; 28: 12023-12031.
73. Qiu J, Xu J, Zheng Y, et al. High-mobility group box 1 promotes metalloproteinase-9 upregulation through Toll-like receptor 4 after cerebral ischemia. Stroke 2010; 41: 2077-2082.
74. Hayakawa K, Qiu J, Lo EH,. Biphasic actions of HMGB1 signaling in inflammation and recovery after stroke. Ann N Y Acad Sci 2010; 1207: 50-57.
75. Zhou Y, Xiong KL, Lin S, et al. Elevation of high-mobility group protein box-1 in serum correlates with severity of acute intracerebral hemorrhage. Mediators Inflamm 2010;2010.pii:142458.
76. Rainer TH, Wong LK, Lam W, et al. Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke. Clin Chem 2003; 49: 562-569.
77. Rainer TH, Wong KS, Lam W, et al. Comparison of plasma beta-globin DNA and S-100 protein concentrations in acute stroke. Clin Chim Acta 2007; 376: 190-196.
78. Distler JH, Pisetsky DS, Huber LC, et al. Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. Arthritis Rheum 2005; 52: 3337-3348.
79. Kuriyama N, Nagakane Y, Hosomi A, et al. Evaluation of factors associated with elevated levels of platelet-derived microparticles in the acute phase of cerebral infarction. Clin Appl Thromb Hemost 2010; 16: 26-32.
80. Jung KH, Chu K, Lee ST, et al. Circulating endothelial microparticles as a marker of cerebrovascular disease. Ann Neurol 2009; 66: 191-199.
81. Simak J, Gelderman MP, Yu H, et al. Circulating endothelial microparticles in acute ischemic stroke: a link to severity, lesion volume and outcome. J Thromb Haemost 2006; 4: 1296-1302.
82. Williams JB, Jauch EC, Lindsell CJ, Campos B,. Endothelial microparticle levels are similar in acute ischemic stroke and stroke mimics due to activation and not apoptosis/necrosis. Acad Emerg Med 2007; 14: 685-690.
83. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr,. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009; 40: 2945-2948.
84. Macleod MR, Davis SM, Mitchell PJ, et al. Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke. Cerebrovasc Dis 2005; 20: 12-17.
85. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999; 282: 2003-2011.
86. Schroeder EB, Rosamond WD, Morris DL, et al. Determinants of use of emergency medical services in a population with stroke symptoms: the Second Delay in Accessing Stroke Healthcare (DASH II) Study. Stroke 2000; 31: 2591-2596.
87. Morris DL, Rosamond WD, Hinn AR, Gorton RA,. Time delays in accessing stroke care in the emergency department. Acad Emerg Med 1999; 6: 218-223.
88. Lacy CR, Suh DC, Bueno M, Kostis JB,. Delay in presentation and evaluation for acute stroke: Stroke Time Registry for Outcomes Knowledge and Epidemiology (S.T.R.O.K.E.). Stroke 2001; 32: 63-69.
89. Kothari RU, Pancioli A, Liu T, et al. Cincinnati Prehospital Stroke Scale: reproducibility and validity. Ann Emerg Med 1999; 33: 373-378.
90. Kidwell CS, Starkman S, Eckstein M, et al. Identifying stroke in the field. Prospective validation of the Los Angeles prehospital stroke screen (LAPSS). Stroke 2000; 31: 71-76.
91. Scott PA, Xu Z, Meurer WJ, et al. Attitudes and beliefs of Michigan emergency physicians toward tissue plasminogen activator use in stroke: baseline survey results from the INcreasing Stroke Treatment through INteractive behavioral Change Tactic (INSTINCT) trial hospitals. Stroke 2010; 41: 2026-2032.
92. Vanni S, Polidori G, Pepe G, et al. Use of biomarkers in triage of patients with suspected stroke. J Emerg Med 2011; 40: 499-505.
93. Pervez MA, Silva G, Masrur S, et al. Remote supervision of IV-tPA for acute ischemic stroke by telemedicine or telephone before transfer to a regional stroke center is feasible and safe. Stroke 2010; 41: e18-e24.
94. Walter S, Kostopoulos P, Haass A, et al. Point-of-care laboratory halves door-to-therapy-decision time in acute stroke. Ann Neurol 2011; 69: 581-586.
95. Klotz E, Konig M,. Perfusion measurements of the brain: using dynamic CT for the quantitative assessment of cerebral ischemia in acute stroke. Eur J Radiol 1999; 30: 170-184.
96. Wintermark M, Reichhart M, Thiran JP, et al. Prognostic accuracy of cerebral blood flow measurement by perfusion computed tomography, at the time of emergency room admission, in acute stroke patients. Ann Neurol 2002; 51: 417-432.
97. Jansen O, Schellinger P, Fiebach J, et al. Early recanalisation in acute ischaemic stroke saves tissue at risk defined by MRI. Lancet 1999; 353: 2036-2037.
98. Kidwell CS, Alger JR, Saver JL,. Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. Stroke 2003; 34: 2729-2735.
99. Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009; 8: 141-150.
100. Montaner J, Perea-Gainza M, Delgado P, et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 2008; 39: 2280-2287.
101. Wunderlich MT, Hanhoff T, Goertler M, et al. Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke. J Neurol 2005; 252: 718-724.
102. Akpinar O, Geyik S, Acikalin A, et al. H-FABP in the early diagnosis of stroke. J Neurol 2009; 256: 1922-1923.
103. Haapaniemi E, Tatlisumak T,. Is D-dimer helpful in evaluating stroke patients? A systematic review. Acta Neurol Scand 2009; 119: 141-150.
104. Di Napoli M, Singh P,. Is plasma fibrinogen useful in evaluating ischemic stroke patients? Why, how, and when. Stroke 2009; 40: 1549-1552.
105. Di Napoli M, Schwaninger M, Cappelli R, et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke 2005; 36: 1316-1329.
106. Blann AD, Ridker PM, Lip GY,. Inflammation, cell adhesion molecules, and stroke: tools in pathophysiology and epidemiology? Stroke 2002; 33: 2141-2143.
107. Pola R,. Inflammatory markers for ischaemic stroke. Thromb Haemost 2009; 101: 800-801.
108. Hashimoto H, Kitagawa K, Hougaku H, et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation 2001; 104: 63-67.
109. Muir KW, Weir CJ, Alwan W, et al. C-reactive protein and outcome after ischemic stroke. Stroke 1999; 30: 981-985.
110. Efstathiou SP, Tsioulos DI, Tsiakou AG, et al. Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke 2005; 36: 1915-1919.
111. Cherubini A, Ruggiero C, Polidori MC, Mecocci P,. Potential markers of oxidative stress in stroke. Free Radic Biol Med 2005; 39: 841-852.
112. Fassbender K, Rossol S, Kammer T, et al. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci 1994; 122: 135-139.
113. Laskowitz DT, Kasner SE, Saver J, et al. Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. Stroke 2009; 40: 77-85.
114. Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009; 119: 2408-2416.
115. Woodward M, Lowe GD, Campbell DJ, et al. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke 2005; 36: 2143-2147.